The company said in a June statement that drugs like Remicade, used to treat conditions like ulcerative colitis, can cost roughly $30,000 annually.
“While life-saving and life-changing, this presents a significant challenge for health plans and can be financially devastating for patients,” the statement said.
Biosimilars are clinically equivalent alternatives to biologics like Remicade, and can reduce drug spending by up to $375 billion over the next decade, according to the statement.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
